Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
ESMO Open
|
June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
E Laakmann, I Witzel, T Neunhöffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
L Gianni, C S Huang, D Egle, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
M Dugo, C-S Huang, D Egle, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
ESMO Open
|
November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
M Schmidt, K Lübbe, T Decker, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
ESMO Open
|
June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
E Laakmann, I Witzel, T Neunhöffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
L Gianni, C S Huang, D Egle, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
M Dugo, C-S Huang, D Egle, et al.
Page
of 6